External Quality Assessment Scheme

Natriuretic peptides 2, B-type, BNP Round 1, 2023

Specimens

Please find enclosed 2 commercial liquid preparations S001 and S002 from human source, each 3 mL. Preservatives and stabilizers are added.

Caution

Quality control specimens derived from human blood must be handled with the same care as patient samples, i.e. as potential transmitters of serious diseases. The specimens are found to be HBsAg, HCVAb and HIVAgAb negative when tested with licensed reagents, but no known test method can offer complete assurance that the specimens will not transmit these or other infectious diseases.

Examinations

BNP

Storage and use

The samples are ready to use and are treated like patient samples. If the sample is frozen when it arrives and you want to analyze it immediately, allow it to thaw for about 20 minutes at room temperature. Then mix the sample for a few minutes before analyzing. Samples stored refrigerated at +2 ... +8 °C are allowed to warm to room temperature for a few minutes before analysis by inverting the vial. Open the flask and transfer the required amount of control to a clean sample cup for analysis. The sample material must not be returned to the original vial.

Result reporting

Please enter the results and methods via LabScala (www.labscala.com). If you cannot find your instrument or reagent from the registry, please contact the EQA coordinator.

S001:



S002:



2023-01-30

INSTRUCTIONS

Product no. 2691 LQ738123011-012/US

If the kit is incomplete or contains damaged specimens, please report immediately to info@labquality.fi

The results should be reported no later than **February 20, 2023**.

Inquiries

EQA Coordinator Satu Eklund satu.eklund@labquality.fi

EQA Coordinator Päivi Ranta paivi.ranta@labquality.fi

Labquality Oy

Kumpulantie 15 FI-00520 HELSINKI Finland


Tel. + 358 9 8566 8200 Fax + 358 9 8566 8280


info@labquality.fi www.labquality.com






BNP |Arc.A





	^x pt	sd	SEM	CV%	n
Abbott Architect & Alinity BNP	42.7 ng/l	6.5	4.6	15.3	2
All methods	48.1 ng/l	10.5	6.1	21.8	3

	^X pt	sd	SEM	CV%	n
Abbott Architect & Alinity BNP	432.5 ng/l	29.0	20.5	6.7	2
All methods	447.7 ng/l	33.3	19.2	7.4	3



Round	Sample	^x pt	Result	diff%	z-score
23/1	Specimen S002	432.5	412.0	-4.7%	-
23/1	Specimen S001	42.7	38.1	-10.8%	-
22/4	Specimen S002	461.4	326.1	-29.3%	-1.08
22/4	Specimen S001	195.7	157.5	-19.5%	-0.88
22/3	Specimen S002	449.6	349.7	-22.2%	-
22/3	Specimen S001	-	20.4	-	-
22/2	Specimen S002	508.3	415.4	-18.3%	-0.63
22/2	Specimen S001	207.1	186.3	-10.1%	-0.49
22/1	Specimen S002	472.6	457.0	-3.3%	-
22/1	Specimen S001	48.4	41.2	-14.8%	-
21/4	Specimen S002	1615.7	1571.7	-2.7%	-0.41
21/4	Specimen S001	40.7	36.7	-9.8%	-0.50

08.03.2023







Report info

Participants

48 participants from 13 countries.

Report info

Your own result should be compared to others using the same method. Assigned values (x_{pt}, target values) are means of the results where results deviating more than +/- 3*standard deviation from the median are removed. The standard uncertainty (u) of

the assigned value is reported as standard error of the mean (SEM). Additionally, if the measurement uncertainty of the target value is large an automatic text is printed on the report: "The uncertainty of the assigned value is not negligible, and evaluations could be affected."
In case the client's result is the only one in the method group, no assigned value will be calculated, no target area shown, and no statistics calculated. In case there are only a few results in the client's own method group, the result can be compared to all method mean or to a group that is similar to the own method.

Results reported with < or > -signs cannot be included in the statistics.

For information on report interpretation and performance evaluation, please see the "EQAS Interpretation guidelines" LabScala User instructions (top right corner? Help link).


08.03.2023 2/2





Sample S001 | NT-proBNP, ng/l


Methodics	x _{pt}	Median	sd	CV%	SEM	min	max	Outliers	n
Alere NT-proBNP Architect & Alinity	353.9	353.8	5.9	1.7	2.4	345.0	362.9	-	6
bioMerieux VIDAS NT-proBNP2	384.0	384.0	5.7	1.5	4.0	380.0	388.0	-	2
Radiometer AQT 90 FLEX NT-proBNP	1014.0	1014.0	45.3	4.5	32.0	982.0	1046.0	-	2
Roche cobas e and Modular E NT-proBNP	349.0	347.0	13.8	4.0	2.4	321.4	380.0	-	33
Roche cobas h232 NT-proBNP	261.7	251.0	41.8	16.0	12.6	209.0	321.0	-	11
Siemens Advia Centaur & Atellica NT-proBNP	-	-	-	-	-	536.0	536.0	-	1
Siemens Dimension & Dimension Vista NT- ProBNP	-	-	-	-	-	129.0	129.0	-	1
All	332.5	345.5	58.1	17.5	7.9	129.0	536.0	2	56

Sample S001 | NT-proBNP, ng/l| histogram summaries in LabScala












07.03.2023

Natriuretic peptides, January, 1-2023











Specimen S001 | BNP, ng/l

Methodics	^x pt	Median	sd	CV%	SEM	min	max	Outliers	n
Abbott Architect & Alinity BNP	42.7	42.7	6.5	15.3	4.6	38.1	47.3	-	2
Quidel Triage / Beckman Coulter BNP	-	-	-	-	-	59.0	59.0	-	1
All	48.1	47.3	10.5	21.8	6.1	38.1	59.0	_	3

Specimen S001 | BNP, ng/l| histogram summaries in LabScala








Sample S002 | NT-proBNP, ng/l


Methodics	^X pt	Median	sd	CV%	SEM	min	max	Outliers	n
Alere NT-proBNP Architect & Alinity	1728.5	1748.1	43.2	2.5	17.6	1648.0	1762.6	-	6
bioMerieux VIDAS NT-proBNP2	2119.0	2119.0	11.3	0.5	8.0	2111.0	2127.0	-	2
Radiometer AQT 90 FLEX NT-proBNP	4556.5	4556.5	178.9	3.9	126.5	4430.0	4683.0	-	2
Roche cobas e and Modular E NT-proBNP	1640.6	1648.0	65.5	4.0	11.4	1505.3	1762.0	-	33
Roche cobas h232 NT-proBNP	1034.3	979.0	147.7	14.3	44.5	837.0	1323.0	-	11
Siemens Advia Centaur & Atellica NT-proBNP	-	-	-	-	-	2100.0	2100.0	-	1
Siemens Dimension & Dimension Vista NT- ProBNP	-	-	-	-	-	783.0	783.0	-	1
All	1537.2	1645.0	315.7	20.5	43.0	783.0	2127.0	2	56

All method groups Radiometer AQT 90 FLEX NT-proBNP (xpt:

Target: ±15%)


4556.5 | Target area: 3873.0-5240.0 |







07.03.2023 4/7

Natriuretic peptides, January, 1-2023








NT- ProBNP




Specimen S002 | BNP, ng/l

Methodics	x _{pt}	Median	sd	CV%	SEM	min	max	Outliers	n
Abbott Architect & Alinity BNP	432.5	432.5	29.0	6.7	20.5	412.0	453.0	-	2
Quidel Triage / Beckman Coulter BNP	-	-	-	-	-	478.0	478.0	-	1
All	447.7	453.0	33.3	7.4	19.2	412.0	478.0	-	3

Specimen S002 | BNP, ng/l| histogram summaries in LabScala







Natriuretic peptides, January, 1-2023

Report info

Participants

48 participants from 13 countries.

Report info

Your own result should be compared to others using the same method. Assigned values (x_{pt}, target values) are means of the results where results deviating more than +/- 3*standard deviation from the median are removed. The standard uncertainty (u) of

the assigned value is reported as standard error of the mean (SEM). Additionally, if the measurement uncertainty of the target value is large an automatic text is printed on the report: "The uncertainty of the assigned value is not negligible, and evaluations could be affected."
In case the client's result is the only one in the method group, no assigned value will be calculated, no target area shown, and no statistics calculated. In case there are only a few results in the client's own method group, the result can be compared to all method mean or to a group that is similar to the own method. Results reported with < or > -signs cannot be included in the statistics.

For information on report interpretation and performance evaluation, please see the "EQAS Interpretation guidelines" LabScala User instructions (top right corner? Help link).

07.03.2023 7/7

External Quality Assessment Scheme

Natriuretic peptides 2, B-type, BNP Round 1, 2023

Specimens

Sample S001 (LQ738123011) and sample S002 (LQ738123012) were commercial liquid human serum samples. Preservatives were added to the samples.

Based on the previous tests and the results of this round, the samples are homogeneous, stable and suitable for the external quality assessment scheme.

The materials were sent without temperature control packaging.

Report info

Please see the description of the data analysis on the last page of the laboratory-specific histogram and Global report. It is important to read the Final report first, because it contains important information of the samples and results in each round.

From round 2, 2021 on the results are reported as ng/L.

Comments - Expert

In this round there were two participants in Abbott Architect & Alinity group and one participant in Quidel Triage / Beckman Coulter -group.

These samples were analysed also in round 3, 2022. Some improvement has occurred, since in previous round variation was larger and some results had to be excluded from statistical evaluation. In the current round variation between the groups was rather reasonable 21.8% (S001) and 7.4% (S002).

End of report

2023-03-24

FINAL REPORT

Product no. 2691

Samples sent 2023-01-30 Round closed 2023-02-20 Report released 2023-03-24

Request for correction

Typing errors in laboratory's result forms are on laboratory's responsibility. Labquality accepts responsibility only for result processing. Requests must be notified by writing within three weeks from the date of this letter.

Authorized by

EQA Coordinator Satu Eklund satu.eklund@labquality.fi

EQA Coordinator Päivi Ranta paivi.ranta@labquality.fi

Expert

M.Sc., Clinical Biochemist, Mia Sneck, HUS Diagnostic center

Labquality Oy

Kumpulantie 15 FI-00520 HELSINKI Finland

Tel. + 358 9 8566 8200 Fax + 358 9 8566 8280

info@labquality.fi www.labquality.com



Copyright © Labquality Oy

Labquality does not permit any reproduction for commercial purposes of any portion of the material subject to this copyright. Labquality prohibits any use of its name, or reference to Labquality EQA program, or material in this report in any advertising, brochures or other commercial publications. Labquality EQA data do not necessarily indicate the superiority of instruments, reagents, testing equipments or materials used by participating laboratories. Use of Labquality EQA data to suggest superiority or inferiority of equipments or materials may be deceptive and misleading. Proficiency test results are handled confidentially. Labquality will not issue any statements to third parties of the performance of laboratories in external quality assessment schemes unless otherwise agreed.